Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Brian Lehpamer (NPI 1093957326)

Field	Value
Entity Type	Individual
Organization	Brian Lehpamer
Address	4414 Lake Boone Trl
City	Raleigh
State	NC
ZIP	27607
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	April 1, 2009

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider’s Medicare portfolio is highly concentrated: total Medicare revenue is $2.9M and the precomputed top 3 Medicare codes (J0178, J2777, 67028) account for 85.7% of that revenue. J0178 alone represents $2M and 67.8% of Medicare revenue, indicating the practice’s economics are heavily driven by aflibercept injections.

Clinical service mix aligns with a retina-focused practice performing frequent intravitreal pharmacologic therapy and retinal diagnostics: high-revenue codes include J0178 (aflibercept), J2777 (faricimab), and 67028 (isolated intravitreal injection), and the top imaging/diagnostic codes 92250 and 92134 appear in the top 25, supporting a workflow centered on anti-VEGF injection clinics plus fundus and OCT imaging. This combination of high-volume injections and imaging is characteristic of a retina specialist who operates regular injection sessions supported by diagnostic testing.

Revenue concentration creates operational and contracting implications: with 67.8% of Medicare revenue tied to J0178 and the top three codes making up 85.7% of Medicare revenue, changes in drug utilization patterns, pricing, or payer reimbursement for these specific codes could materially affect practice revenue. Payers and analysts should treat this provider as having concentrated drug-procedure exposure rather than a broad procedure mix.

Competitive standing for J0178 is strong — the provider ranks #208 of 3204 nationally (94th percentile) and is described as notably above typical national volume, which signals this clinician is a relatively high-volume aflibercept injector versus peers. By contrast, J2777 ranks #816 of 2039 (60th percentile) and 67028 ranks #630 of 4255 (85th percentile), both labeled as typical or unremarkable volumes, so dominance appears focused specifically on J0178 rather than across all anti-VEGF products or injection codes.

Several services show outlier-level utilization in ancillary diagnostics and office visits: 92250 ranks #80 of 25087 providers nationally (100th percentile; extreme outlier) and 99213 ranks #4831 of 457151 providers nationally (99th percentile; extreme outlier). These positions suggest the provider bills fundus photography and a high volume of level-3 E&M visits relative to peers, consistent with frequent follow-up and imaging tied to ongoing intravitreal therapy.

The provider’s payer mix is effectively single-payer at scale: Medicare revenue is $2.9M while there is no Medicaid billing on file. Analysts should consider the practice as primarily Medicare-facing for negotiated rates and utilization reviews, with minimal to zero Medicaid exposure to influence revenue or access patterns.

Coding breadth is consistent with advanced retinal care including interventional and surgical codes: lower-volume but specialized procedures such as 67228 (laser for diabetic retinopathy) and 67108 (retinal detachment repair) appear in the top 25, indicating the clinician performs some procedural and surgical interventions in addition to injection-based therapy. These codes are described as typical, unremarkable volumes, suggesting occasional use rather than a high-volume surgical practice.

Provider tenure is long-standing: the NPI was enumerated 2009-04-01 (~17 years ago), indicating an established practice history that supports observed high-volume injection activity and sustained Medicare billing patterns. This longevity, combined with concentrated anti-VEGF revenue and imaging/outpatient visit outlier ranks, frames the provider as an experienced, injection-focused retina specialist with material Medicare exposure.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	2,850	$690	$2M
J2777	Injection, faricimab‑svoa, 0.1 mg	12,840	$30	$372.4K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,660	$90	$147.7K
J2778	Injection, ranibizumab, 0.1 mg	560	$180	$101.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,120	$60	$67.4K
J3590	Unclassified biologics	20	$2,570	$48.8K
92250	Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,…	1,490	$30	$37.1K
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	210	$170	$36.5K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	1,260	$30	$34.1K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	170	$110	$19.1K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Brian Lehpamer — 5 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	7	100	950	$690	$881K
J2777	38	70	12,990	$30	$503.7K
Q5124	5	10	890	$170	$259K
J2778	26	50	620	$180	$202.2K
J3590	11	10	30	$2,570	$95K
67028	24	120	780	$90	$80K
67108	10	20	10	$960	$15.3K
99214	11,762	18,060	110	$80	$15.1K
J9035	40	90	140	$50	$13.4K
92235	20	70	60	$100	$8.7K

Showing 1–10 of 19

Related Providers

Other providers that share a Tax Identification Number (TIN) with Brian Lehpamer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
Charles Wykoff	TX	Ophthalmology Physician	$6.2M	$0
Shil Patel	VA	Ophthalmology Physician	$6.1M	$0
Matthew Benz	TX	Ophthalmology Physician	$5.7M	$0
David Brown	TX	Ophthalmology Physician	$5.7M	$0
James Pate	NC	Ophthalmology Physician	$5.2M	$0
Nitin Gupta	NC	Ophthalmology Physician	$4.7M	$0
Tien Wong	TX	Ophthalmology Physician	$4.5M	$0
Jay Wang	FL	Medical Oncology Physician	$4.5M	$0
Joseph Sedrak	TX	MOHS-Micrographic Surgery Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Brian Lehpamer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Autism Society Of North Carolina, Inc.	NC	Community/Behavioral Health Agency	$0	$95.7M
Rex Hospital Inc.	NC	General Acute Care Hospital	$0	$25.3M
Bayada Home Health Care, Inc.	NC	Home Health Agency	$0	$24.8M
Nc Dept Of Health And Human Service	NC	Clinical Medical Laboratory	$0	$16.4M
Jeffers Mann & Artman Pediatric & Adolesent Medicine PA	NC	Pediatric Adolescent Medicine Physician	$0	$10.9M
Pediatric Therapy Associates	NC	Physical Therapist	$0	$10.2M
Blue Ridge Day Surgery Center, LP	NC	Ambulatory Surgical Clinic/Center	$1.6M	$2.2M
John Thordsen	NC	Retina Specialist (Ophthalmology) Physician	$3.5M	$0
Rebecca Manning	NC	Retina Specialist (Ophthalmology) Physician	$3.4M	$0
Sachin Mudvari	NC	Retina Specialist (Ophthalmology) Physician	$3.2M	$0

Brian Lehpamer — Billing Profile & Reimbursement Data

Sign up for Brian Lehpamer — Billing Profile & Reimbursement Data policy alerts

Brian Lehpamer — Billing Profile & Reimbursement Data

Sign up for Brian Lehpamer — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References